CAR T-cell therapy for multiple myeloma: state of the art and prospects - The Lancet Haematology
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma | Journal of Experimental & Clinical Cancer Research | Full Text
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design | PLOS ONE
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells | Molecular Pharmaceutics
IJMS | Free Full-Text | Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
IJMS | Free Full-Text | Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice - Parikh - CA: A Cancer Journal for Clinicians - Wiley Online Library
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma | Journal of Hematology & Oncology | Full Text
IJMS | Free Full-Text | Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
Lytic Capacity of Lower Affinity CD38-CAR T Cells toward Multiple... | Download Scientific Diagram
Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells - ScienceDirect
CD38 CAR-T Cell Therapy May Be Promising for Patients With Multiple Myeloma - Hematology Advisor
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells | Molecular Pharmaceutics
CD38: An important regulator of T cell function - ScienceDirect
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma | Haematologica
Pan-heme CAR: Anti-CD38 CAR T cells for myeloid, lymphoid and plasma cell malignancies | Leukemia and Lymphoma Society
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
Cureus | Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma | Article
CAR-T Cell Therapy Target Proteins | Sino Biological
New Strategies for Targeting CD38 in Multiple Myeloma Take Root
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design | PLOS ONE
Construction of anti-CD38 CAR T cells and its expression. A: Schematic... | Download Scientific Diagram
Anti-CD38 CAR-T - Multiple Myeloma Clinical Trials
Frontiers | Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
Driving Out Chronic Lymphocytic Leukemia With CAR T Cells - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma | Haematologica
